Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
The association between RAPGEF6 and schizophrenia is supported by multiple well‐powered genetic studies. Two independent multi-patient studies have demonstrated that risk haplotypes spanning RAPGEF6, along with nearby genes, are significantly associated with schizophrenia in distinct populations (PMID:18718982) (PMID:17030554). These studies collectively evaluated cohorts including a Han Chinese case-control series with 506 patients and replication in several family-based cohorts, such as 267 families comprising 1337 subjects, thereby providing robust statistical evidence for the gene-disease association.
The clinical validity of this association is rated as Strong. Multiple cohorts and replication studies across different ethnic groups have consistently identified risk haplotypes—in some cases exhibiting sex-specific associations—with odds ratios in the range of twofold to 10-fold increased risk. Although the studies did not report individual coding variants with a formal HGVS notation, the aggregated genetic evidence from large cohorts and extensive family segregation analyses underpins the strong classification (PMID:18718982) (PMID:17030554).
In terms of genetic evidence, the association was derived from haplotype analyses involving numerous markers across a critical interval. The data support that variants in RAPGEF6 are contributing to schizophrenia risk via haplotype effects rather than via single, high-penetrance coding mutations. Despite the absence of sequence-level HGVS variant details applicable to RAPGEF6 in these studies, the observed replicated associations across diverse cohorts lend significant weight to the genetic findings. This evidence meets ClinGen criteria for a strong genetic association by incorporating replication in multiple independent studies and demonstrating statistical robustness.
The available functional evidence for RAPGEF6 in schizophrenia remains limited. While there is a functional assessment study showing that BAG3 interacts with a guanine nucleotide exchange factor (PDZGEF2) in the context of metastatic malignant neoplasm (PMID:20800573), this experimental work was performed in a different disease context and does not directly test the neurobiological mechanisms underlying schizophrenia. Thus, there is a disconnection between the strong genetic associations and the scarce functional data relevant to schizophrenia. This gap highlights the need for focused functional assays to elucidate the pathogenic mechanism by which RAPGEF6 may modulate brain function.
No strong conflicting evidence has been reported in the genetic association studies; however, the absence of directly relevant functional validation in neuronal systems underscores a limitation in the current evidence base. It is important for future work to bridge this gap by developing in vitro and in vivo models that directly assess how RAPGEF6 variants influence neurodevelopment or neurotransmission. At present, the genetic data are robust and consistent, even if the functional studies have not yet reached the same level of relevance for schizophrenia pathogenesis.
In conclusion, RAPGEF6 shows a strong genetic association with schizophrenia based on replicated haplotype data from multiple well‐characterized cohorts. Although direct functional evidence linking RAPGEF6 to neurobiological changes in schizophrenia is limited, the genetic findings are compelling and support its potential utility in diagnostic decision-making, commercial genetic testing, and future publication. Key take‑home sentence: RAPGEF6 is a strong candidate gene for schizophrenia, warranting further functional investigation to elucidate its role in disease pathogenesis.
Gene–Disease AssociationStrongMultiple robust cohorts, including a Han Chinese series with 506 patients and a family study of 267 families (1337 subjects), consistently demonstrate significant association across independent studies (PMID:18718982) (PMID:17030554). Genetic EvidenceStrongHaplotype-based association studies across different ethnic cohorts, with replication and statistically significant risk estimates, support RAPGEF6 as contributing to schizophrenia risk even in the absence of individual sequence-level variant data. Functional EvidenceLimitedFunctional studies directly assessing RAPGEF6 in schizophrenia are lacking; available experimental data are from a cancer-related context and do not address neurobiological mechanisms. |